Abstract
Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
Keywords: Combined therapy, hematologic malignancies, histone deacetylase inhibitors, monotherapy, panobinostat, solid tumors.
Current Drug Targets
Title:Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Volume: 15 Issue: 6
Author(s): Xiaoyang Li, Jian Zhang, Yuanchao Xie, Yuqi Jiang, Zhang Yingjie and Wenfang Xu
Affiliation:
Keywords: Combined therapy, hematologic malignancies, histone deacetylase inhibitors, monotherapy, panobinostat, solid tumors.
Abstract: Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
Export Options
About this article
Cite this article as:
Li Xiaoyang, Zhang Jian, Xie Yuanchao, Jiang Yuqi, Yingjie Zhang and Xu Wenfang, Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer, Current Drug Targets 2014; 15 (6) . https://dx.doi.org/10.2174/1389450115666140306152642
DOI https://dx.doi.org/10.2174/1389450115666140306152642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Equinatoxin II Potentiates Temozolomide- and Etoposide-Induced Glioblastoma Cell Death
Current Topics in Medicinal Chemistry EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer
Mini-Reviews in Medicinal Chemistry Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry The Screening of Renoprotective Agents by 99mTc-DMSA: A Review of Preclinical Studies
Current Radiopharmaceuticals Developing Antitumor Magnetic Hyperthermia: Principles, Materials and Devices
Recent Patents on Anti-Cancer Drug Discovery Serine Protease Inhibitors and T Lymphocyte Immunity
Current Immunology Reviews (Discontinued) Microglial Activation with Reduction in Autophagy Limits White Matter Lesions and Improves Cognitive Defects During Cerebral Hypoperfusion
Current Neurovascular Research Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Recent Patents on Regenerative Medicine